for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.O

Latest Trade

234.46USD

Change

0.00(0.00%)

Volume

8,678

Today's Range

--

 - 

--

52 Week Range

54.21

 - 

238.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
234.46
Open
0.00
Volume
8,678
3M AVG Volume
202.49
Today's High
--
Today's Low
--
52 Week High
238.40
52 Week Low
54.21
Shares Out (MIL)
401.53
Market Cap (MIL)
89,516.60
Forward P/E
9.07
Dividend (Yield %)
--

Next Event

Q2 2021 Moderna Inc Earnings Release

Latest Developments

More

Moderna Provides A Clinical Update On The Neutralizing Activity Of Its Covid-19 Vaccine On Emerging Variants Including The Delta Variant First Identified In India

U.S. FDA Says Revisions To Patient And Provider Fact Sheets For Moderna, Pfizer-Biontech COVID-19 Vaccines On Increased Risks Of Myocarditis,Pericarditis

Moderna Plans To Expand Production To Make COVID-19 Vaccine Boosters, Supply More Countries- WSJ

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Moderna Inc

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Industry

Biotechnology & Drugs

Contact Info

200 Technology Sq

Cambridge, MA

02139-3578

United States

+1.617.7146500

https://www.modernatx.com/

Executive Leadership

Noubar B. Afeyan

Non-Executive Independent Chairman of the Board, Co-Founder

Stephen Hoge

President

Stephane Bancel

Chief Executive Officer, Director

David W. Meline

Chief Financial Officer

Tracey Franklin

Chief Human Resources Officer

Key Stats

2.53 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.8K

2021(E)

18.3K
EPS (USD)

2018

-4.950

2019

-1.550

2020

-1.960

2021(E)

24.572
Price To Earnings (TTM)
177.76
Price To Sales (TTM)
32.77
Price To Book (MRQ)
23.29
Price To Cash Flow (TTM)
140.54
Total Debt To Equity (MRQ)
4.77
LT Debt To Equity (MRQ)
3.60
Return on Investment (TTM)
19.34
Return on Equity (TTM)
8.10

Latest News

Latest News

Moderna's COVID-19 vaccine shows promise against Delta variant in lab study

Moderna Inc's COVID-19 vaccine showed promise against the Delta variant first identified in India in a lab study, with a modest decrease in response compared to the original strain, the drugmaker said on Tuesday.

India's Cipla gets nod to distribute partner Moderna's COVID vaccine

Indian drugmaker Cipla Ltd has received regulatory approval to distribute partner Moderna Inc's COVID-19 vaccine in the country, a senior government official said on Tuesday, clearing the way for the shot to be imported.

Moderna's COVID-19 vaccine shows promise against Delta variant in lab study

Moderna Inc said on Tuesday its COVID-19 vaccine produced neutralizing antibodies against emerging variants, including the delta variant first identified in India, in a lab study.

Factbox: Countries vaccinating children against COVID-19

Moderna is seeking a green light for using its COVID-19 vaccine for teens as young as 12 in the EU, United States and Canada, as Pfizer - whose shot is already being administered - plans tests on even younger children.

India grants emergency approval for Moderna's COVID-19 vaccine - govt official

India's Cipla Ltd has been granted a new drug permission for restricted use of Moderna Inc's COVID-19 vaccine in the country, a senior government official said on Tuesday.

Moderna SE Asia partner says regional vaccine supplies booked until year-end

Zuellig Pharma, Moderna's supply partner for COVID-19 vaccines in Southeast Asia, said on Tuesday that regional orders for the mRNA vaccine were almost fully booked for this year, highlighting procurement challenges for countries slow off the mark.

Moderna SE Asia partner says regional vaccine supplies booked to year-end

Zuellig Pharma, Moderna Inc's supply partner for COVID-19 vaccines in Southeast Asia, said on Tuesday that regional orders for the mRNA vaccine were almost fully booked for this year.

Sanofi to invest 400 million euros in a mRNA vaccines facility

Sanofi said it will invest about 400 million euros ($476.4 million) in research and development of next-generation vaccines using mRNA technologies, which proved their efficiency in the Pfizer and Moderna COVID-19 vaccines.

Vietnam approves Moderna's COVID-19 vaccine for emergency use

Vietnam's health ministry said in a statement on Tuesday it had approved Moderna Inc's COVID-19 vaccine for emergency use, making it the country's fifth vaccine to be approved as authorities seek to accelerate an inoculation programme.

Germany expects faster Moderna COVID-19 vaccine deliveries

Germany expects drugmaker Moderna Inc to deliver COVID-19 vaccines faster than expected, helping it ramp up vaccinations in coming months, the health ministry said on Sunday.

U.S. FDA adds warning about rare heart inflammation to Pfizer, Moderna COVID vaccines

The U.S. drug regulator on Friday added a warning to the literature that accompanies Pfizer Inc/BioNTech and Moderna COVID vaccine shots to indicate the rare risk of heart inflammation after its use.

U.S. FDA adds warning about rare heart inflammation to Pfizer, Moderna COVID vaccines

The U.S. drug regulator on Friday added a warning to the literature that accompanies Pfizer Inc /BioNTech and Moderna vaccine shots to indicate the rare risk of heart inflammation after its use.

Booster may be needed for J&J shot as Delta variant spreads, some experts already taking them

Infectious disease experts are weighing the need for booster shots of the Pfizer/BioNTech or Moderna mRNA-based vaccines for Americans who received Johnson & Johnson's one-dose vaccine due to the increasing prevalence of the more contagious Delta coronavirus variant.

FDA to add warning about rare heart inflammation to Pfizer, Moderna vaccines

The U.S. Food and Drug Administration said on Wednesday it plans to move quickly to add a warning about rare cases of heart inflammation in adolescents and young adults to fact sheets for the Pfizer/BioNTech and Moderna COVID-19 vaccines.

U.S. panel to review heart inflammation cases after Pfizer, Moderna vaccines

Advisers to the U.S. Centers for Disease Control and Prevention (CDC) are set to meet on Wednesday to assess the possibility of a link between rare cases of heart inflammation and the mRNA COVID-19 vaccines from Pfizer and partner BioNTech and from Moderna.

EU takes up option to buy 150 million more Moderna COVID-19 shots

The European Union has decided to take up an option under a supply contract with drugmaker Moderna that allows the bloc to order 150 million additional COVID-19 vaccines produced by the U.S. biotech firm, the EU Commission said on Tuesday.

Study testing Moderna vaccine in transmission prevention to include young adults

U.S. scientists are expanding a government-funded study that aims to directly answer the question of whether Moderna Inc's COVID-19 vaccine curbs the spread of SARS-CoV-2.

EU takes up option to buy 150 million more Moderna COVID-19 vaccines

The European Union has decided to take up an option under a supply contract with drugmaker Moderna that allows the bloc to order 150 million additional COVID-19 vaccines produced by the U.S. biotech firm, the EU Commission said on Tuesday.

WHO setting up hub to make COVID-19 vaccines in South Africa

The WHO is setting up a hub in South Africa to give companies from poor and middle-income countries the know-how and licenses to produce COVID-19 vaccines, in what President Cyril Ramaphosa called an historic step to spread lifesaving technology.

Moderna plans to expand COVID-19 vaccine production: WSJ

Moderna Inc is adding two new production lines at its COVID-19 vaccine manufacturing plant in Massachusetts, in a bid to prepare for making more booster shots, the Wall Street Journal reported on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up